mitter dopamine appears to be associated with abnormalities related to disorders such as Parkinson's disease and schizophrenia. The highest density of dopamine neurons occurs in the nigrostriatal dopamine pathway which degenerates in Parkinson's disease (1). Neuroleptic drugs elicit extrapyramidal parkinsonian side effects by blocking dopamine receptors in the corpus striatum and also exert antischizophrenic action by blocking dopamine receptors, perhaps in limbic areas (2) . Numbers of dopamine receptors are increased by chronic neuroleptic treatment (3) and are also increased in some schizophrenics, perhaps mitter dopamine appears to be associated with abnormalities related to disorders such as Parkinson's disease and schizophrenia. The highest density of dopamine neurons occurs in the nigrostriatal dopamine pathway which degenerates in Parkinson's disease (1). Neuroleptic drugs elicit extrapyramidal parkinsonian side effects by blocking dopamine receptors in the corpus striatum and also exert antischizophrenic action by blocking dopamine receptors, perhaps in limbic areas (2) . Numbers of dopamine receptors are increased by chronic neuroleptic treatment (3) and are also increased in some schizophrenics, perhaps possible to relate regional biochemistry within the human brain to measurements of behavior in normal subjects and to elucidate abnormalities in patients with Alzheimer's disease (5), Huntington's disease (6), depression (7), and multiple infarct dementia (8) . The technique consists of intravenous injection of a substance such as '8F-labeled deoxyglupossible to relate regional biochemistry within the human brain to measurements of behavior in normal subjects and to elucidate abnormalities in patients with Alzheimer's disease (5), Huntington's disease (6), depression (7), and multiple infarct dementia (8) . The technique consists of intravenous injection of a substance such as '8F-labeled deoxyglucose, [lC]carboxyhemoglobin, ionic rubidium-82, 68Ga-labeled EDTA, and other radiopharmaceuticals, and subsequent imaging of the distribution of the radioactive label in the brain by means of the tomographic method, based on detection of the annihilation radiation produced during positron emission (9) .
The butyrophenone neuroleptic drug spiperone has been useful in binding studies for measuring dopamine receptors both in vitro (10) Prior to injection, the product was purified and the specific activity was determined by using a reverse-phase liquid chromatographic column (EM brand Lichrosorb column RP 18). The specific activity was also determined by an in vitro competitive binding assay. Although the nonradioactive and radioactive syntheses were carried out by new methods (12), the compound was previously reported in a patent by Janssen (13).
Whether a ligand is binding to receptors in vivo can be determined by testing whether the regional distribution of radioactivity after drug injection parallels the distribution of receptors, and also by testing whether administration of excess, unlabeled, related drugs block this specific regional distribution. For example, the rat striatum has very high concentrations of dopamine receptors while the cerebellum has very low levels (11). Thus, high striatal/cerebellar ratios of injected drug indicate the successful, preferential labeling of dopamine receptors in vivo (11) . The content of drug in the cerebellum is a measure of nonspecific or non-receptor-associated drug in brain while the striatal content reflects total drug, that is, both specific and nonspecific binding. Administration of excess unlabeled neuroleptic drugs with high affinity for dopamine receptors obliterates the regional distribution (11) .
In experiments in vitro, we found that NMSP has a binding affinity for dopamine receptors similar to that of spiperone (14). In preliminary studies in vivo, we tested whether NMSP would be localized at dopamine receptors as spiperone is. ["C]NMSP (55 mCi/Vmole; the dose was 10 pg per kilogram of body weight) was injected into the tail veins of mice. After sacrificing the animals and dissecting the brain regions, we found that striatal activity was 15 to 20 times greater than cerebellar radioactivity at 60 minutes after injection. Coinjection of unlabeled spiperone lowered the high striatal/cerebellar ratios by 70 percent at spiperone doses of 150 tpg/kg without altering cerebellar binding. These biochemical studies indicate that NMSP is a suitable ligand for labeling dopamine receptors in vivo.
The next experiments involved PET imaging in anesthetized baboons. Intravenous injections of 16 mCi of ["C]NMSP (specific activity, 223 Ci/mmole) were administered in three separate studies. Preferential accumulation of radioactivity in the caudate nucleus and putamen was observed as early as 15 minutes after injection in scans on all occasions.
In one of these studies, two injections separated by 3 hours were given. The ed tracer selectively concentrated in the first injection consisted of []C]NMSP region of the caudate nucleus and putawith a specific activity of 10.4 mCi/[L-men relative to the rest of the brain. mole (the dose was 21 fg/kg). The inject-After the carbon-11 had been allowed to (Table 2 and Fig. 2 ). This has been observed in many animal studies and is due mainly to the reduction of nonspecific binding in the cerebellum and remainder of brain ( 1). Figure 2 , A and B, shows the unprocessed PET images. The basal ganglia were again seen, with slightly less activity in the rest of the brain. Activity in other regions, particularly in the cerebral cortex, could reflect serotonin-2 receptors, which are also labeled by neuroleptic drugs (15).
The planes for PET imaging in the human and baboon studies were selected after x-ray computed tomography (CT) images identified planes for examining the basal ganglia. Moreover, the location of the high concentrations of activity within the brain slice corresponded to the location of the basal ganglia as determined by the CT scans. A headholder was used to ensure ease and reproducibility of locating the planes. The eyes were out of the planes imaged in the human study (16). The caudate/cerebellar ratio of radioactivity was 4 at 70 to 130 minutes after injection in the human and 2 at 40 to 60 minutes in baboons. These ratios are underestimates of the true activity distribution because of physical factors including partial volume and resolution effects (17).
In summary, ["C]NMSP, a compound 1266 
